Base de dados : MEDLINE
Pesquisa : C02.256.466.382.316 [Categoria DeCS]
Referências encontradas : 1112 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 112 ir para página                         

  1 / 1112 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953684
[Au] Autor:Ying X; Wang H; Deng S; Chen Y; Zhang J; Yu W
[Ad] Endereço:aDepartment of Neurosurgery, Hangzhou First People's Hospital, Zhejiang Chinese Medical University bDepartment of Neurosurgery, Hangzhou First People's Hospital, Nanjing Medical University cDepartment of Anesthesia and Pain Medicine, Tonglu First People's Hospital, Hangzhou, Zhejiang, P.R. China.
[Ti] Título:Long-term outcome of percutaneous balloon compression for trigeminal neuralgia patients elder than 80 years: A STROBE-compliant article.
[So] Source:Medicine (Baltimore);96(39):e8199, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This article evaluates the long-term outcome of percutaneous balloon compression (PBC) for trigeminal neuralgia (TN) patients elder than 80 years. A total of 138 elderly patients aged above 80 years with primary TN, who were admitted to Neurosurgery Department, Hangzhou First People's Hospital from January 2007 to December 2011 for PBC treatment, were retrospectively analyzed in this study. The postoperative cure rate of immediate pain was 98.6% (Barrow Neurological Institute [BNI] classes I, II); according to the follow-up, the pain cure rates at 1, 2, 3, 4, and 5 years after surgery were 93.5%, 90.4%, 84.7%, 80.4%, and 72.9%, respectively. In our group, postoperative diplopia was reported in 1 case, masticatory muscle weakness in 3 cases, and herpes labialis in 19 cases. A total of 100% of pain-cured patients exhibited facial numbness and facial hypoesthesia. No serious complications occurred in this group of patients. PBC is an effective and safe procedure for TN treatment and can be employed as the preferred regimen for elderly TN patients aged above 80 years in poorer physical condition.
[Mh] Termos MeSH primário: Diplopia
Herpes Labial
Debilidade Muscular
Procedimentos Neurocirúrgicos
Complicações Pós-Operatórias
Neuralgia do Trigêmeo
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
China
Diplopia/diagnóstico
Diplopia/etiologia
Feminino
Herpes Labial/diagnóstico
Herpes Labial/etiologia
Seres Humanos
Masculino
Debilidade Muscular/diagnóstico
Debilidade Muscular/etiologia
Exame Neurológico/métodos
Procedimentos Neurocirúrgicos/efeitos adversos
Procedimentos Neurocirúrgicos/métodos
Avaliação de Processos e Resultados (Cuidados de Saúde)
Medição da Dor/métodos
Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/etiologia
Recidiva
Estudos Retrospectivos
Neuralgia do Trigêmeo/diagnóstico
Neuralgia do Trigêmeo/fisiopatologia
Neuralgia do Trigêmeo/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008199


  2 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28301628
[Au] Autor:Rosen T
[Ti] Título:Recurrent Herpes Labialis in Adults: New Tricks for an Old Dog.
[So] Source:J Drugs Dermatol;16(3):s49-s53, 2017 Mar 01.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:

Herpes labialis remains a common worldwide affliction. Recent advances in understanding the basic pathogenesis have led to new therapeutic intervention, both on-label and off-label. Aside from reducing the duration and symptomatology of acute outbreaks, another goal of treatment is to decrease the frequency of future episodes. Oral and topical acyclovir and its analogues are the mainstay of both chronic suppressive and episodic therapy. A new muco-adhesive formulation of acyclovir provides a decrease in outbreaks, probably due to a diminution of herpesvirus load in all reservoir sites. Acyclovir-resistant strains are rare in immunocompetent hosts; parenteral foscarnet and cidofovir are administered in this situation. Parenteral acyclovir is the drug of choice for eczema herpeticum, which may begin as herpes labialis in an atopic dermatitis patient. Thermotherapy may be beneficial, and a certified device to deliver heat is available outside the United States.

J Drugs Dermatol. 2017;16(3 Suppl):s49-53.

.
[Mh] Termos MeSH primário: Antivirais/administração & dosagem
Antivirais/uso terapêutico
Herpes Labial/terapia
Herpesvirus Humano 1/efeitos dos fármacos
Estomatite Herpética/terapia
Carga Viral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Aciclovir/administração & dosagem
Aciclovir/uso terapêutico
Administração Oral
Administração Tópica
Adulto
Doença Crônica/terapia
Citosina/administração & dosagem
Citosina/análogos & derivados
Citosina/uso terapêutico
Farmacorresistência Viral
Foscarnet/administração & dosagem
Foscarnet/uso terapêutico
Herpes Labial/complicações
Herpesvirus Humano 1/isolamento & purificação
Herpesvirus Humano 1/fisiologia
Seres Humanos
Hipertermia Induzida
Infusões Parenterais
Organofosfonatos/administração & dosagem
Organofosfonatos/uso terapêutico
Recidiva
Estomatite Herpética/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Organophosphonates); 364P9RVW4X (Foscarnet); 8J337D1HZY (Cytosine); JIL713Q00N (cidofovir); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE


  3 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28017747
[Au] Autor:Huang X; Xu M; Xu J; Zhou L; Zhong P; Chen M; Ji K; Chen H; Mao Y
[Ad] Endereço:Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
[Ti] Título:Complications and Management of Large Intracranial Vestibular Schwannomas Via the Retrosigmoid Approach.
[So] Source:World Neurosurg;99:326-335, 2017 Mar.
[Is] ISSN:1878-8769
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate the common complications from the microsurgical treatment of large intracranial vestibular schwannoma (VS) via suboccipital retrosigmoid approach and to propose strategies for minimizing such complications. METHODS: We selected all patients with large unilateral VS from the collected database (1999-2013) who underwent microsurgical resection as their initial treatment for histopathologically confirmed VS. Tumors larger than 30 × 20 mm were defined as large. RESULTS: A total of 1167 patients with VS were included. Gross total tumor resection was achieved in 1006 patients (86.2%). The mortality rate is 0.77%. The facial nerve was preserved anatomically in 1083 cases (92.8%), and the functional valuation of the facial nerve according to postoperative House-Brackmann scale showed 423 patients (36.2%) in grades I-II, 534 cases (45.8%) in grade III, and 210 patients (18.0%) in grade IV-VI. The main short-term postoperative complication included new hearing loss (American Institute of Otolaryngology-Head and Neck Surgery grade D) in 634 cases (54.3%), disequilibrium in 250 cases (21.4%), labial herpes in 127 cases (10.9%), meningitis in 115 (9.85%) and lower cranial nerve deficit in 77 cases (6.59%). Follow-up data were available for 978 of the 1167 patients (83.8%). Long-term complications include hearing loss (American Institute of Otolaryngology-Head and Neck Surgery grade D) (75.8%), permanent facial paralysis (11.9%), facial numbness (10.9%), tinnitus (2.96%), chronic headache (2.25%), and taste disturbance (1.43%). CONCLUSIONS: The key factors for reducing surgical complications include careful assessment of the functions of acoustic and facial nerves as well as a thorough understanding of anatomy via the retrosigmoid approach before operation, skillful microsurgical technique, and monitoring of multiple cranial nerves during resection.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/cirurgia
Paralisia Facial/epidemiologia
Perda Auditiva/epidemiologia
Neuroma Acústico/cirurgia
Procedimentos Neurocirúrgicos/métodos
Complicações Pós-Operatórias/epidemiologia
Doenças Vestibulares/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias Encefálicas/patologia
Criança
Doenças dos Nervos Cranianos/epidemiologia
Feminino
Cefaleia/epidemiologia
Herpes Labial/epidemiologia
Seres Humanos
Hipestesia/epidemiologia
Masculino
Meningite/epidemiologia
Meia-Idade
Neuroma Acústico/patologia
Estudos Retrospectivos
Distúrbios do Paladar/epidemiologia
Zumbido/epidemiologia
Carga Tumoral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161227
[St] Status:MEDLINE


  4 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Cherubini, Karen
[PMID]:27866178
[Au] Autor:Spanemberg JC; Figueiredo MA; Cherubini K; Salum FG
[Ti] Título:Low-level Laser Therapy: A Review of Its Applications in the Management of Oral Mucosal Disorders.
[So] Source:Altern Ther Health Med;22(6):24-31, 2016 Nov.
[Is] ISSN:1078-6791
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Due to its analgesic, anti-inflammatory, and biostimulating effects, low-level laser therapy (LLLT) has been widely used for oral disorders, such as oral lichen planus (OLP), xerostomia, recurrent aphthous stomatitis (RAS), herpes labialis, burning mouth syndrome (BMS), and oral mucositis (OM). The research team for the present study has reviewed the literature on the subject, with an emphasis on the applicability of LLLT in general and of its various clinical protocols for the management of those oral disorders. In lesions such as the ones occurring in OM, RAS, herpes labialis, and OLP, the course of wound healing and the pain have been shown to decrease, with a few, or most often, no adverse side effects. The literature shows that LLLT can also be effective in reducing symptoms in patients with BMS. For the treatment of hyposalivation and xerostomia, the use of LLLT has been described in the literature, but no consensus has resulted. Very few controlled clinical studies with well-established therapeutic protocols have occurred, except for OM, for which LLLT has been widely researched. Although information on the use of the laser for some lesions has already been consolidated, further research is needed, especially randomized, controlled clinical trials with long-term follow-up. Those studies will allow the safe use of LLLT, permitting the creation of care protocols for the management of oral disorders.
[Mh] Termos MeSH primário: Terapia com Luz de Baixa Intensidade
Doenças da Boca/radioterapia
Ensaios Clínicos Controlados Aleatórios como Assunto
[Mh] Termos MeSH secundário: Síndrome da Ardência Bucal/radioterapia
Herpes Labial
Seres Humanos
Líquen Plano Bucal/radioterapia
Estomatite/radioterapia
Estomatite Herpética/radioterapia
Resultado do Tratamento
Xerostomia/radioterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161121
[St] Status:MEDLINE


  5 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27635861
[Au] Autor:Leplina O; Starostina N; Zheltova O; Ostanin A; Shevela E; Chernykh E
[Ad] Endereço:a Institite of Fundamental and Clinical Immunology , Novosibirsk , Russia.
[Ti] Título:Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study.
[So] Source:Hum Vaccin Immunother;12(12):3029-3035, 2016 12.
[Is] ISSN:2164-554X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recurrent herpes simplex labialis caused predominantly with herpes simplexvirus 1(HSV-1) is a major problem, for which various treatments have minimal impact. Given the important role of the immune system in controlling virus infection, an activation of virus-specific immune responses, in particular,using dendritic cell (DCs) vaccines, seems to be a promising approach for the treatment of patients with frequent recurrences of herpes labialis. The current paper presents the results of a pilot study of the safety and efficacy of DC vaccines in 14 patients with recurrent HSV-1 infections. DCs were generated in presence of GM-CSF and IFN-alpha and were loaded with HSV-1 recombinant viral glycoprotein D (HSV1gD). DCs cells were injected subcutaneously as 2 courses of vaccination during 9 months. Immunotherapy with DCs did not induce any serious side effects and resulted in more than 2-fold reduction in the recurrence rate and significant enhancement of the inter-recurrent time during the 9 months of treatment and subsequent 6-month follow-up period. An obvious clinical improvement was accompanied with an induction of an antigen-specific response to HCV1gD and a normalization of reduced mitogenic responsiveness of mono-nuclear cells. According to long-term survey data (on average 48 months after the beginning of therapy), 87% of respondents reported the decreased incidence of recurrent infection. At this time, most patients (85.7%) responded to HCV1gD stimulation. The data obtained suggests that dendritic cell vaccines may be a promising new approach for the treatment of recurrent labial herpes.
[Mh] Termos MeSH primário: Células Dendríticas/imunologia
Herpes Labial/terapia
Vacinas contra o Vírus do Herpes Simples/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Vacinas contra o Vírus do Herpes Simples/administração & dosagem
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Prevenção Secundária
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Herpes Simplex Virus Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171112
[Lr] Data última revisão:
171112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160917
[St] Status:MEDLINE
[do] DOI:10.1080/21645515.2016.1214348


  6 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27527631
[Au] Autor:Choksi TT; Madison G; Dar T; Asif M; Fleming K; Clarke L; Danilewitz M; Hennawy R
[Ad] Endereço:Department of Internal Medicine, Mercy Philadelphia Hospital, Philadelphia, Pennsylvania. ttchoksi@hotmail.com.
[Ti] Título:Multiorgan Dysfunction Syndrome from Strongyloides stercoralis Hyperinfection in a Patient with Human T-Cell Lymphotropic Virus-1 Coinfection After Initiation of Ivermectin Treatment.
[So] Source:Am J Trop Med Hyg;95(4):864-867, 2016 Oct 05.
[Is] ISSN:1476-1645
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Strongyloides stercoralis is well known to cause hyperinfection syndrome during the period of immunosuppression; but dissemination, worsening hyperinfection, and development of multiorgan dysfunction syndrome after initiation of ivermectin has not been reported in the past. Herein, we describe the case of a 62-year-old man with chronic strongyloidiasis and human T-cell lymphotropic virus-1 coinfection, who developed significant clinical worsening after 24-48 hours of initiation of treatment with ivermectin (200 µg/kg daily). Oral albendazole (600 mg every 12 hours) was added to the regimen due to clinical deterioration. Notably, after a protracted clinical course with multiple complications, which included respiratory failure from gram-negative pneumonia and pulmonary alveolar hemorrhage, Klebsiella meningitis, Clostridium difficile colitis, and herpes labialis, the patient eventually recovered. Health-care providers should be aware that during the early days of antihelminthic treatment initiation, significant dissemination of S. stercoralis and worsening of the clinical scenario can occur.
[Mh] Termos MeSH primário: Antiparasitários/efeitos adversos
Infecções por HTLV-I/complicações
Ivermectina/efeitos adversos
Insuficiência de Múltiplos Órgãos/etiologia
Estrongiloidíase/tratamento farmacológico
[Mh] Termos MeSH secundário: Albendazol/uso terapêutico
Animais
Antiparasitários/uso terapêutico
Coinfecção
Enterocolite Pseudomembranosa/complicações
Infecções por Bactérias Gram-Negativas/complicações
Herpes Labial/complicações
Vírus 1 Linfotrópico T Humano
Seres Humanos
Ivermectina/uso terapêutico
Infecções por Klebsiella/complicações
Masculino
Meningites Bacterianas/complicações
Meia-Idade
Pneumonia Bacteriana/complicações
Insuficiência Respiratória/complicações
Strongyloides stercoralis
Estrongiloidíase/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparasitic Agents); 70288-86-7 (Ivermectin); F4216019LN (Albendazole)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160817
[St] Status:MEDLINE


  7 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27272090
[Au] Autor:Rosen T
[Ti] Título:Pragmatic and Profound Benefits of Acyclovir Buccal Adhesive Tablets.
[So] Source:J Drugs Dermatol;15(6):775-7, 2016 Jun 01.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The clinician has many options, both systemic and topical, for the management of oro-labial herpes simplex infections due to HSV-1. A recent addition to this armamentarium is Acyclovir 50 mg Buccal Adhesive Tablets (ABT 50mg). While this agent demonstrates the typical modest reduction in time to healing of any given episode of recurrent oro-labial HSV 1, it also was found in pivotal studies to alter the course of this troublesome viral disease. Several case reports are presented which dramatically illustrate that ABT 50mg can reduce the overall number of overt outbreaks and increase the time interval between outbreaks in patients with historical evidence of frequent episodes. This therapeutic intervention is thus: simple, safe, efficacious and cost-effective, even in patients who experience numerous (and therefore disconcerting) oro-labial outbreaks.

J Drugs Dermatol. 2016;15(6):775-777.
[Mh] Termos MeSH primário: Aciclovir/administração & dosagem
Adesivos/administração & dosagem
Herpes Labial/diagnóstico
Herpes Labial/tratamento farmacológico
Mucosa Bucal
[Mh] Termos MeSH secundário: Administração Bucal
Idoso
Feminino
Seres Humanos
Masculino
Mucosa Bucal/efeitos dos fármacos
Comprimidos
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adhesives); 0 (Tablets); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170426
[Lr] Data última revisão:
170426
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE


  8 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27210517
[Au] Autor:Guergué Diaz de Cerio O; Rubio Lombraña M; Barrutia Borque A; González Hermosa MR
[Ad] Endereço:Servicio de Dermatología del Hospital Universitario Cruces, Vizcaya, Spain. Electronic address: olaneguergue06051988@gmail.com.
[Ti] Título:Father-to-Newborn Transmission of Herpes Simplex Virus Infection: A Sweet but Bitter Kiss.
[So] Source:Actas Dermosifiliogr;107(9):797-798, 2016 Nov.
[Is] ISSN:1578-2190
[Cp] País de publicação:Spain
[La] Idioma:eng; spa
[Mh] Termos MeSH primário: Relações Pai-Filho
Gestos
Herpes Simples/transmissão
[Mh] Termos MeSH secundário: Aciclovir/uso terapêutico
Adulto
Antivirais/uso terapêutico
Diagnóstico Precoce
Encefalite por Herpes Simples/prevenção & controle
Pai
Feminino
Herpes Labial/transmissão
Herpes Simples/tratamento farmacológico
Herpes Simples/virologia
Herpesvirus Humano 1/isolamento & purificação
Seres Humanos
Recém-Nascido
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160524
[St] Status:MEDLINE


  9 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27031826
[Au] Autor:Moon SY; Lee WJ; Lee SJ; Kim do W; Jang YH
[Ad] Endereço:Department of Dermatology, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
[Ti] Título:Pathological evidence of foreign body reaction induced by bee sting therapy.
[So] Source:J Cutan Pathol;43(7):623-5, 2016 Jul.
[Is] ISSN:1600-0560
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Abelhas
Reação a Corpo Estranho/etiologia
Herpes Labial/terapia
Mordeduras e Picadas de Insetos/complicações
Medicina Tradicional Coreana
[Mh] Termos MeSH secundário: Animais
Feminino
Reação a Corpo Estranho/patologia
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160401
[St] Status:MEDLINE
[do] DOI:10.1111/cup.12681


  10 / 1112 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27025259
[Au] Autor:Jiang YC; Feng H; Lin YC; Guo XR
[Ad] Endereço:State Key Laboratory of Oral Disease, West China School of Stomatology, Sichuan University, Chengdu, China.
[Ti] Título:New strategies against drug resistance to herpes simplex virus.
[So] Source:Int J Oral Sci;8(1):1-6, 2016 Mar 30.
[Is] ISSN:2049-3169
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Herpes simplex virus (HSV), a member of the Herpesviridae family, is a significant human pathogen that results in mucocutaneous lesions in the oral cavity or genital infections. Acyclovir (ACV) and related nucleoside analogues can successfully treat HSV infections, but the emergence of drug resistance to ACV has created a barrier for the treatment of HSV infections, especially in immunocompromised patients. There is an urgent need to explore new and effective tactics to circumvent drug resistance to HSV. This review summarises the current strategies in the development of new targets (the DNA helicase/primase (H/P) complex), new types of molecules (nature products) and new antiviral mechanisms (lethal mutagenesis of Janus-type nucleosides) to fight the drug resistance of HSV.
[Mh] Termos MeSH primário: Antivirais/farmacologia
Resistência a Medicamentos
Herpes Labial/tratamento farmacológico
Nucleosídeos/farmacologia
Extratos Vegetais/farmacologia
Simplexvirus/efeitos dos fármacos
Estomatite Herpética/tratamento farmacológico
[Mh] Termos MeSH secundário: Aciclovir/farmacologia
Antivirais/química
Seres Humanos
Hospedeiro Imunocomprometido
Estrutura Molecular
Mutagênese/efeitos dos fármacos
Nucleosídeos/química
Extratos Vegetais/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Nucleosides); 0 (Plant Extracts); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:160331
[St] Status:MEDLINE
[do] DOI:10.1038/ijos.2016.3



página 1 de 112 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde